Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Cognitive Test Analysis May Determine Reliable MS Change Over Time
Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair
Neuroprotection mediated through estrogen receptor-alpha in astrocytes.
Cerebrospinal fluid data compilation and knowledge-based interpretation of bacterial, viral, parasitic, oncological, chronic inflammatory and demyelinating diseases. Diagnostic patterns not to be missed in neurology and psychiatry.
Experimental models of spontaneous autoimmune disease in the central nervous system.
The MS Microbiome Consortium (MSMC): an academic multi-disciplinary collaborative effort to elucidate the role of the gut microbiota in MS
Episode 23 with Professor Aksel Siva discussing radiologically isolated syndrome (RIS)
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort.
Management of worsening multiple sclerosis with mitoxantrone: a review.
[Usefulness of electronic drug registers: Spanish register of patients treated with fingolimod (Gilenya ®)].
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
Demyelination of the hippocampus is prominent in the cuprizone model.
Teriflunomide modest help but safe for MS
Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination.
FGF2 and FGFR1 signaling regulate functional recovery following cuprizone demyelination.
HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica.
Gene expression in brain during cuprizone-induced demyelination and remyelination.
28th Congress of European Committee for Treatment and Research in Multiple Sclerosis Congress
Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
Episode 1 with Dr. Timothy Vollmer on maintaining brain health
Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS.
Origin, fate and dynamics of macrophages at central nervous system interfaces.
New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Quantifying the early stages of remyelination following cuprizone-induced demyelination.

Pages